deltatrials
Terminated PHASE3 NCT00660595

Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

Sponsor: AstraZeneca

Conditions Schizophrenic Disorders
Interventions Quetiapine Risperidone
Updated 7 times since 2017 Last updated: Aug 24, 2010 Started: Sep 30, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

A PHASE3 clinical study on Schizophrenic Disorders, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Harjavalta, Finland
  • • Helsinki, Finland
  • • Pitkäniemi, Finland
  • • Turku, Finland